Quodra

Quodra is a biotechnology company focused on developing a new class of small molecule medicines that modulate the activity of RNA-binding proteins (RBPs). By targeting RBPs, which are critical regulators of gene expression and cellular function, the company aims to address diseases with high unmet needs that have been historically difficult to treat. Quodra's platform combines advanced structural biology, computational screening, and medicinal chemistry to identify and optimize small molecules capable of binding to specific RBP sites. The company's initial research efforts are directed toward therapeutic areas such as metabolic diseases, oncology, and neurology. Quodra operates as an early-stage drug discovery entity, leveraging its proprietary insights into RBP-RNA interactions to build a robust pipeline of precision therapies.